HKEX Filings
-
Oct 14, 2025
Voluntary announcement - Clover announces positive phase I clinical data for RSV-HMPV-PIV3 combination vaccines and for RSV re-vaccination in older adults
-
Oct 3, 2025Monthly Return of Equity Issuer on Movements in Securities for the Month ended September 30, 2025
-
Sep 18, 20252025 Interim Report
-
Sep 4, 2025Monthly Return of Equity Issuer on Movements in Securities for the Month ended August 31, 2025
-
Aug 27, 2025Interim Results Announcement for the Six Months Ended June 30, 2025
-
Aug 14, 2025Date of Board Meeting
-
Aug 5, 2025Monthly Return of Equity Issuer on Movements in Securities for the Month ended July 31, 2025
-
Jul 3, 2025Monthly Return of Equity Issuer on Movements in Securities for the Month ended June 30, 2025
-
Jul 2, 2025List of Directors and their Roles and Functions
-
Jul 2, 2025Nomination Committee - Terms of Reference
-
Jun 19, 2025Poll Results of the Annual General Meeting Held on June 19, 2025 and Retirement of Non-Executive Director
-
Jun 19, 2025List of Directors and their Roles and Functions
-
Jun 17, 2025Voluntary Announcement Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-
Jun 16, 2025Voluntary Announcement Termination of Cooperation with Adimmune
-
Jun 9, 2025Inside Information
-
Jun 5, 2025Monthly Return of Equity Issuer on Movements in Securities for the Month ended May 31, 2025
-
May 21, 2025Circular (1) proposed grant of general mandates to repurchase shares and to issue new shares and/or sell or transfer treasury shares; (2) proposed re-election of the retiring directors; (3) proposed appointment of auditor; and (4) notice of annual general meeting
-
May 21, 2025Notice of General Annual Meeting
-
May 21, 2025Form of Proxy for Use at Annual General Meeting
-
May 21, 2025Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
